Journal article icon

Journal article

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Abstract:

PURPOSE: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetic/pharmacodynamic profile, and antitumor activity in patients with advanced solid tumors. PATIENTS AND METHODS: An initial dose escalation was conducted using a once-daily dosing schedule, with oral RO4987655 administered at doses of 1.0 to 2.5 mg once daily over 28 co...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research More from this journal
Volume:
18
Issue:
17
Pages:
4794-4805
Publication date:
2012-09-01
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
Language:
English
Keywords:
Pubs id:
pubs:350956
UUID:
uuid:6a9e1511-fba6-4ed6-9b5e-dc52ed5a8a99
Local pid:
pubs:350956
Source identifiers:
350956
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP